NCT05608044进行中（未招募）2 期
A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination With Balstilimab (AGEN2034) or Investigator's Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- Agenus Inc.
- 入组人数
- 234
- 试验地点
- 65
- 主要终点
- Objective Response Rate
研究概览
简要总结
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.
详细描述
This study will enroll adult participants with a confirmed diagnosis of unresectable metastatic colorectal adenocarcinoma (CRC) who have had prior chemotherapy for metastatic or recurrent CRC.
This study will consist of 5 cohorts. In the first and second cohorts, participants will receive 1 of 2 different doses of botensilimab intravenously (IV) and balstilimab IV. In the third and fourth cohorts, participants will receive 1 of 2 different doses of botensilimab. In the fifth cohort, participants will receive standard of care consisting of the investigator's choice of regorafenib or trifluridine and tipiracil.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of unresectable and metastatic CRC adenocarcinoma.
- •The tumor must have been assessed for microsatellite instability high (MSI-H) or deficient mismatch repair (dMMR) status per a standard local testing method.
- •Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study-specific procedures.
- •Must have received at least 1 prior chemotherapy regimen for metastatic or recurrent CRC as follows where approved and locally available in the country of randomization:
- •Standard chemotherapy/therapy including all of the following agents (if eligible and no contraindication): a fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab or biosimilars, an anti-epidermal growth factor receptor antibody (cetuximab or panitumumab), and v-raf murine sarcoma viral oncogene homolog B1 inhibitor/BRAF (encorafenib), if applicable.
- •Participants must have progressed while receiving or within 3 months of the last administration of their last line of standard therapy or be unable to tolerate any of these standard treatments.
- •Participants who received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy can count this as a line of therapy.
- •Measurable disease on baseline imaging per RECIST 1.
- •Life expectancy ≥ 12 weeks.
- •Eastern Cooperative Oncology Group performance status of 0 or
- •Adequate organ function.
- •Women of childbearing potential must have a negative serum pregnancy test at screening and prior to study drug administration.
- •Male participants with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study, starting with the Screening visit through 2-6 months, depending upon assigned study treatment. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.
- •No growth factor support, transfusions, or albumin administration within 14 days of randomization of study treatment.
排除标准
- •Tumor is MSI-H/dMMR per a standard local testing method.
- •Received programmed cell death protein 1, PD-(L)1, or CTLA-4 therapies including any immune checkpoint inhibitor or experimental immunologic agents.
- •Received regorafenib or trifluridine/tipiracil as prior therapy(ies).
- •Partial or complete bowel obstruction within the last 3 months, signs/symptoms of bowel obstruction, or known radiologic evidence of impending obstruction.
- •Refractory ascites.
- •Liver metastases by computed tomography or magnetic resonance imaging. Note: Participants with definitively treated liver metastases (this includes surgical resection, including microwave or radiofrequency ablation, or stereotactic body radiation therapy, but not yttrium-90 or chemotherapy alone) may be eligible if they were treated at least 6 months prior to enrollment with no evidence of metastatic disease in the liver on subsequent imaging.
- •Clinically significant (that is, active) cardiovascular disease.
- •Active brain metastases or leptomeningeal metastases with certain exceptions.
- •Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment. Participants with history of prior early-stage basal/squamous cell skin cancer, low-risk prostate cancer eligible for active surveillance, or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible.
- •Treatment with one of the following classes of drugs within the delineated time window prior to Cycle 1 Day 1 (C1D1):
- •Cytotoxic, targeted therapy or other investigational therapy within 3 weeks.
- •Monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or similar therapy, within 4 weeks, or 5 half-lives, whichever is shorter.
- •Small molecule/tyrosine kinase inhibitors within 2 weeks or less than 5 circulating half-lives of investigational drug.
- •Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
- •Any evidence of current interstitial lung disease (ILD) or pneumonitis, or prior history of ILD or non-infectious pneumonitis requiring glucocorticoids.
- •History of allogeneic organ transplant, stem cell transplant, or bone marrow transplant.
- •Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
- •Participants with a condition requiring systemic treatment with either corticosteroids (> 10 milligrams [mg] daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent) are permitted in the absence of active autoimmune disease.
- •Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (that is, with use of disease-modifying agents or immunosuppressive drugs).
- •History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.
- •Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D
- •Uncontrolled infection with human immunodeficiency virus.
- •Known to be positive for hepatitis B virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection.
- •Known active hepatitis C virus as determined by positive serology and confirmed by polymerase chain reaction.
- •Has urine protein ≥ 1 gram/24 hour.
- •Uncontrolled hypertension: systolic pressure ≥ 150 millimeters of mercury (mmHg) or diastolic pressure ≥ 90 mmHg on repeated measurements that cannot be managed by standard antihypertension medications ≤ 28 days before the first dose of study drug(s).
- •Participants who require treatment with strong cytochrome P450 3A4 inducers or inhibitors.
- •Has presence of gastrointestinal condition, for example, malabsorption, that might affect the absorption of study drug(s).
- •Non-healing wound(s).
- •Symptomatic active bleeding.
研究组 & 干预措施
Combination Botensilimab Dose 1 plus Balstilimab
Experimental
Participants will receive botensilimab at dose 1 given IV and balstilimab given IV.
干预措施: Botensilimab (Drug)
Combination Botensilimab Dose 1 plus Balstilimab
Experimental
Participants will receive botensilimab at dose 1 given IV and balstilimab given IV.
干预措施: Balstilimab (Drug)
Combination Botensilimab Dose 2 plus Balstilimab
Experimental
Participants will receive botensilimab at dose 2 given IV and balstilimab given IV.
干预措施: Botensilimab (Drug)
Combination Botensilimab Dose 2 plus Balstilimab
Experimental
Participants will receive botensilimab at dose 2 given IV and balstilimab given IV.
干预措施: Balstilimab (Drug)
Monotherapy Botensilimab Dose 1
Experimental
Participants will receive botensilimab dose 1 given IV.
干预措施: Botensilimab (Drug)
Monotherapy Botensilimab Dose 2
Experimental
Participants will receive botensilimab dose 2 given IV.
干预措施: Botensilimab (Drug)
Standard of Care
Active Comparator
Participants will receive select standard of care as determined by the investigator.
干预措施: Standard of Care (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: First dose through up to 2 years
Objective response rate is defined as the proportion of participants with complete response or partial response, as assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
次要结局
- Duration of Response(First dose through up to 2 years)
- Progression-free Survival(First dose through up to 3 years)
- Overall Survival(First dose through up to 3 years)
- Number of Participants Experiencing Treatment-emergent Adverse Events(First dose through up to 2 years)
- Serum Botensilimab Concentration(First study dose (pre-dose and 1 hour post-dose) through up to 2 years)
- Serum Balstilimab Concentration(First study dose (pre-dose and 1 hour post-dose) through up to 2 years)
- Number of Participants Positive for Botensilimab Anti-drug Antibodies Following Treatment with Botensilimab(First study dose (pre-dose and 1 hour post-dose) through up to 2 years)
- Number of Participants Positive for Balstilimab Anti-drug Antibodies Following Treatment with Balstilimab(First study dose (pre-dose and 1 hour post-dose) through up to 2 years)
研究者
研究点 (65)
Loading locations...
相似试验
已完成
2 期
A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 DiseaseBatten DiseaseJansky-Bielschowsky DiseaseLate-Infantile Neuronal Ceroid Lipofuscinosis Type 2CLN2 DiseaseCLN2 DisorderNCT02678689BioMarin Pharmaceutical14
撤回
2 期
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT04100330AVEO Pharmaceuticals, Inc.
终止
2 期
LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune HepatitisAutoimmune HepatitisNCT00608894Veloxis Pharmaceuticals13
终止
2 期
Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT00151736Cephalon88
已完成
2 期
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)Estrogen Receptor Positive TumorHER2-positive Breast CancerBreast CancerNCT03644186ETOP IBCSG Partners Foundation147
相关资讯
Balstilimab Plus Botensilimab Shows Enhanced Response in MSS mCRC Without Liver Metastases- Preliminary phase 2 data shows balstilimab combined with botensilimab yields a higher objective response rate in MSS mCRC patients without liver metastases.
- The combination of botensilimab 75 mg Q6W plus balstilimab showed a confirmed ORR of 19% and a disease control rate of 55%.
- The median duration of response has not been reached, with 70% of responses ongoing, indicating durable efficacy of the combination therapy.
- A phase 3 trial is planned using botensilimab 75 mg with balstilimab 240 mg, based on the favorable safety and efficacy profile observed.last yearFDA Advises Against Accelerated Approval for Botensilimab/Balstilimab in MSS Colorectal Cancer Despite Phase 3 Advancement- The FDA advised against accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases, citing concerns that objective response rates may not translate to survival benefit.
- Phase 2 trial data showed the combination achieved a 19.4% objective response rate with the 75 mg botensilimab dose, significantly higher than the 0% response rate seen with standard of care treatment.
- Despite the regulatory setback, Agenus and the FDA agreed on dosing for a phase 3 study, with botensilimab 75 mg every 6 weeks for up to 4 doses plus balstilimab 240 mg every 2 weeks for up to 2 years.
- The company remains committed to advancing the combination therapy and is exploring partnership opportunities to conduct the phase 3 trial in the United States.2 years agoFDA Grants Fast Track Designation to Botensilimab Plus Balstilimab for Non-MSI-H/dMMR mCRC- The FDA has granted Fast Track designation to botensilimab plus balstilimab for treating non-MSI-H/dMMR metastatic colorectal cancer (mCRC).
- The designation targets heavily pretreated patients resistant or intolerant to standard therapies, including fluoropyrimidine, oxaliplatin, irinotecan, VEGF inhibitors, EGFR inhibitors, and BRAF inhibitors.
- Phase 1a/b trial data showed an overall response rate of 23% and a disease control rate of 76% in patients with microsatellite stable, refractory mCRC treated with the combination.
- The median overall survival was not reached in the overall population, with a 12-month overall survival rate of 63%, highlighting the potential of this combination in a high unmet need setting.3 years ago